Marc H. Glickman net worth and biography

Marc Glickman Biography and Net Worth

Marc H. Glickman, M.D. has served as our Senior Vice President and Chief Medical Officer since May 2016 and served as member of our board of directors from July 2016 to August 2017. In 1981, Dr. Glickman started a vascular practice in Norfolk, Virginia. He established the first Vein Center in Virginia and also created a dialysis access center. He was employed by Sentara Health Care as director of Vascular Services until he retired in 2014. Dr. Glickman is a board-certified vascular surgeon. Dr. Glickman received his Doctor of Medicine from Case Western Reserve, in Cleveland, Ohio and completed his residency at the University of Washington, Seattle. He is board certified in Vascular Surgery and was the past president of the Vascular Society of the Americas. He has served on the advisory boards of Possis Medical, Cohesion Technologies, Thoratec, GraftCath, Inc., TVA medical, Austin, Texas.

What is Marc H. Glickman's net worth?

The estimated net worth of Marc H. Glickman is at least $9,856.00 as of May 21st, 2021. Dr. Glickman owns 1,600 shares of enVVeno Medical stock worth more than $9,856 as of September 26th. This net worth estimate does not reflect any other assets that Dr. Glickman may own. Learn More about Marc H. Glickman's net worth.

How do I contact Marc H. Glickman?

The corporate mailing address for Dr. Glickman and other enVVeno Medical executives is 70 DOPPLER, IRVINE CA, 92618. enVVeno Medical can also be reached via phone at (949) 261-2900. Learn More on Marc H. Glickman's contact information.

Has Marc H. Glickman been buying or selling shares of enVVeno Medical?

Marc H. Glickman has not been actively trading shares of enVVeno Medical during the past quarter. Most recently, on Friday, May 21st, Marc H. Glickman bought 1,600 shares of enVVeno Medical stock. The stock was acquired at an average cost of $5.90 per share, with a total value of $9,440.00. Following the completion of the transaction, the senior vice president now directly owns 1,600 shares of the company's stock, valued at $9,440. Learn More on Marc H. Glickman's trading history.

Who are enVVeno Medical's active insiders?

enVVeno Medical's insider roster includes Robert Berman (CEO), Francis Duhay (Director), Marc Glickman (SVP), Robert Gray (Director), and Matthew Jenusaitis (Director). Learn More on enVVeno Medical's active insiders.

Are insiders buying or selling shares of enVVeno Medical?

In the last year, enVVeno Medical insiders bought shares 5 times. They purchased a total of 15,251 shares worth more than $91,541.14. The most recent insider tranaction occured on August, 16th when Director Francis Duhay bought 7,751 shares worth more than $47,591.14. Insiders at enVVeno Medical own 1.9 % of the company. Learn More about insider trades at enVVeno Medical.

Information on this page was last updated on 8/16/2022.

Marc H. Glickman Insider Trading History at enVVeno Medical

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
5/21/2021Buy1,600$5.90$9,440.001,600View SEC Filing Icon  
See Full Table

Marc H. Glickman Buying and Selling Activity at enVVeno Medical

This chart shows Marc H Glickman's buying and selling at enVVeno Medical by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

enVVeno Medical Company Overview

enVVeno Medical logo
enVVeno Medical Corporation (Nasdaq: NVNO) is an medical device company focused on the development of innovative bioprosthetic (tissue-based) devices to improve the standard of care in the treatment of venous disease. The company’s lead product, the VenoValve®️, is a first-in-class, surgical implant being developed for the treatment of severe deep venous Chronic Venous Insufficiency (CVI). Deep venous CVI occurs when valves inside of the deep veins of the leg become damaged, resulting in insufficient blood being returned to the heart. The malfunctioning vein valves cause blood to flow backwards (reflux) and pool in the lower leg, increasing the pressure within the veins of the leg (venous hypertension). In the most severe cases, CVI can lead to venous ulcers (open skin sores) that become chronic and difficult to heal. The VenoValve is implanted in the femoral vein and works as a replacement venous valve, designed to reduce reflux and venous hypertension, and to restore proper directional blood flow back to the heart. With severe deep venous CVI impacting an estimated 2.4 million people in the U.S., who have no effective treatment options, the VenoValve has received Breakthrough Device Designation from the U.S. Food and Drug Administration, and is currently being evaluated in the SAVVE U.S. clinical trial.
Read More

Today's Range

Now: $6.16
Low: $6.00
High: $6.46

50 Day Range

MA: $6.38
Low: $4.98
High: $7.82

2 Week Range

Now: $6.16
Low: $3.35
High: $11.38


82,500 shs

Average Volume

39,473 shs

Market Capitalization

$58.34 million

P/E Ratio


Dividend Yield